Neve Stephen La Buys 20,000 Shares of Accuray (NASDAQ:ARAY) Stock

Accuray Incorporated (NASDAQ:ARAY) CEO Neve Stephen La purchased 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average cost of $0.97 per share, with a total value of $19,400.00. Following the completion of the transaction, the chief executive officer owned 20,000 shares in the company, valued at $19,400. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Accuray Stock Down 4.8%

NASDAQ:ARAY traded down $0.05 during mid-day trading on Wednesday, hitting $0.92. The company had a trading volume of 1,543,873 shares, compared to its average volume of 822,578. The business has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $1.47. The company has a current ratio of 1.65, a quick ratio of 0.92 and a debt-to-equity ratio of 1.53. Accuray Incorporated has a 1 year low of $0.91 and a 1 year high of $2.95. The firm has a market capitalization of $104.82 million, a price-to-earnings ratio of -46.24 and a beta of 1.39.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.13). The company had revenue of $93.94 million during the quarter, compared to analysts’ expectations of $91.34 million. Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%. Accuray has set its FY 2026 guidance at EPS. Equities analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ARAY. Wall Street Zen lowered shares of Accuray from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. BTIG Research lowered their price target on shares of Accuray from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Accuray in a report on Thursday, November 13th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ARAY. Vanguard Group Inc. grew its holdings in Accuray by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,476,677 shares of the medical equipment provider’s stock worth $9,146,000 after acquiring an additional 106,087 shares in the last quarter. Heartland Advisors Inc. increased its holdings in Accuray by 11.8% in the first quarter. Heartland Advisors Inc. now owns 4,274,750 shares of the medical equipment provider’s stock valued at $7,652,000 after buying an additional 450,000 shares during the last quarter. Armistice Capital LLC increased its holdings in Accuray by 2.7% in the third quarter. Armistice Capital LLC now owns 3,324,000 shares of the medical equipment provider’s stock valued at $5,551,000 after buying an additional 88,000 shares during the last quarter. Geode Capital Management LLC raised its stake in Accuray by 7.8% during the second quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider’s stock valued at $3,318,000 after buying an additional 174,703 shares in the last quarter. Finally, Acuitas Investments LLC lifted its holdings in Accuray by 67.7% during the 3rd quarter. Acuitas Investments LLC now owns 2,392,126 shares of the medical equipment provider’s stock worth $3,995,000 after buying an additional 966,100 shares during the last quarter. 64.08% of the stock is currently owned by institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.